ROGER JEFFS
CIK 1231615 · Chief Executive Officer · last filed 2026-07-14
"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.
Loading insider history…
Disclosed Exposure
$232.64M
Companies
6
Total Filings
375
Lifetime Open-Market Net
-$193.91M
Holdings By Company
Latest on-record share count from this person's most recent non-derivative Form 4 transaction in each company. Disclosed exposure = shares × current underlying price.
| Symbol | Role | Shares | Price | Disclosed Exposure | Lifetime OM Net | Filings | Latest Filed |
|---|---|---|---|---|---|---|---|
| LQDA | Chief Executive Officer | 2,207,342 | $90.22 | $199.15M | -$32.44M | 39 | 2026-07-14 |
| AXSM | Director | 105,565 | $212.74 | $22.46M | -$15.63M | 31 | 2026-06-11 |
| ALBIREO PHARMA, INC. (ALBO) Delisted | Director | — | $44.15 | — | $0 | 6 | 2021-06-28 |
| Dova Pharmaceuticals Inc. (DOVA) Delisted | Director | 0 | — | — | $701.9K | 7 | 2019-11-12 |
| SANGAMO THERAPEUTICS, INC (SGMO) Delisted | Director | 9,908 | $0.18 | $1.8K | $100.5K | 3 | 2018-09-07 |
| UTHR | President & Co-CEO | 20,486 | $538.84 | $11.04M | -$146.64M | 268 | 2016-03-15 |
Recent Filings · Page 5 of 38
375 filingsInsider activity across all companies, newest first. Form 4 rows are post-trade confirmations (buys, sells, grants, exercises). Notice (144) rows are pre-trade notices of intent to sell restricted or control stock under Rule 144 — they may not all execute. Compare adjacent dates to see which notices became actual sales.
| Filed | Symbol | Action | Net Shares | Net $ | Link |
|---|---|---|---|---|---|
| 2025-06-05 | LQDA | Mixed | +38,559 | -$519.5K | EDGAR |
| 2025-04-16 | LQDA | Sell (S) | −14,130 | -$191.7K | EDGAR |
| 2025-02-25 | AXSM | Grant (A) | — | $0 | EDGAR |
| 2025-01-14 | LQDA | Mixed | +206,984 | -$263.2K | EDGAR |
| 2024-10-15 | LQDA | Sell (S) | −8,053 | -$89.5K | EDGAR |
| 2024-07-15 | LQDA | Sell (S) | −8,053 | -$100.9K | EDGAR |
| 2024-06-11 | AXSM | Grant (A) | — | $0 | EDGAR |
| 2024-04-16 | LQDA | Sell (S) | −8,360 | -$121.9K | EDGAR |
| 2024-03-19 | LQDA | Sell (S) | −28,583 | -$452.2K | EDGAR |
| 2024-03-15 | AXSM | Notice (144) | −2,347 | -$168.1K | EDGAR |
Form 4 codes: P = open-market purchase · S = open-market sale · A = grant/award · M = option exercise · F = tax withholding at vest · G = bona-fide gift · D = disposition to issuer · J = other (see filing footnote). Only P / S codes carry directional signal.
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.